12-Dec-2025
UNCY Faces Federal Securities Fraud Class Action Allegations Over FDA Compliance Disclosures
Market Chameleon (Thu, 4-Dec 6:36 AM ET)
Globe Newswire (Wed, 3-Dec 9:13 AM ET)
Globe Newswire (Tue, 2-Dec 12:39 PM ET)
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
Globe Newswire (Tue, 25-Nov 7:05 AM ET)
Globe Newswire (Fri, 14-Nov 9:26 AM ET)
Globe Newswire (Thu, 13-Nov 5:40 PM ET)
OLC Pill Burden Data and Cash Runway Strengthen Unicycive’s Path Toward NDA Resubmission
Market Chameleon (Wed, 12-Nov 6:59 AM ET)
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
Globe Newswire (Wed, 12-Nov 7:05 AM ET)
Globe Newswire (Mon, 10-Nov 9:42 AM ET)
Globe Newswire (Mon, 3-Nov 7:05 AM ET)
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Unicycive Therapeutics trades on the NASDAQ stock market under the symbol UNCY.
As of December 12, 2025, UNCY stock price declined to $6.23 with 246,885 million shares trading.
UNCY has a beta of 1.69, meaning it tends to be more sensitive to market movements. UNCY has a correlation of 0.13 to the broad based SPY ETF.
UNCY has a market cap of $133.89 million. This is considered a Micro Cap stock.
Last quarter Unicycive Therapeutics reported $0 in Revenue and -$.46 earnings per share. This fell short of revenue expectation by $-265,620 and exceeded earnings estimates by $.09.
In the last 3 years, UNCY traded as high as $28.70 and as low as $2.02.
The top ETF exchange traded funds that UNCY belongs to (by Net Assets): VTI, VXF.
UNCY has underperformed the market in the last year with a price return of -22.1% while the SPY ETF gained +13.4%. However, in the short term, UNCY had mixed performance relative to the market. It has outperformed in the last 3 months, returning +52.3% vs +3.9% return in SPY. But in the last 2 weeks, UNCY shares have been beat by the market, returning -1.1% compared to an SPY return of +0.3%.
UNCY support price is $6.08 and resistance is $6.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that UNCY shares will trade within this expected range on the day.
